Trial · NCT01436227
Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome
NCT01436227, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2025-05-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome. Trials, record NCT01436227. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01436227
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome
- NCT number
- NCT01436227
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 32 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Von Hippel-Lindau Syndrome
- Interventions
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride
- First posted
- 2011-09-19
- Last updated
- 2025-05-02
- Results first posted
- 2025-05-02
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (Complete Response + Partial Response) | At 24 weeks | Overall response rate (complete response + partial response) Determined by the Response Evaluation Criteria in Solid Tumors. Estimated with its corresponding 95% posterior credible interval. |
| Primary | Progressive Disease Rate | Up to 24 weeks | Progressive disease rate |
| Primary | Drug Discontinuation Due to Toxicity | Up to 24 weeks | Drug discontinuation due to toxicity |
| Primary | Time to Progression (TTP) | Up to 24 weeks | TTP will be estimated using the Kaplan-Meier method. Log-rank test will be performed to test the difference in survival between prognostic groups. Regression analyses of survival data based on the Cox proportional hazards model will be conducted on TTP. The proportional hazards assumption will be evaluated graphically and analytically, and regression diagnostics (e.g., martingale and Shoenfeld residuals) will be examined to ensure that the models are appropriate. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate (Complete Response + Partial Response) | At 24 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Progressive Disease Rate | Up to 24 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Drug Discontinuation Due to Toxicity | Up to 24 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Time to Progression (TTP) | Up to 24 weeks | Days | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (Complete Response + Partial Response) | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 13 | Participants | ||
| Progressive Disease Rate | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 6 | Participants | ||
| Drug Discontinuation Due to Toxicity | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 7 | Participants | ||
| Time to Progression (TTP) | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | NA | Standard Deviation NA | Days |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 32 | |
| Overall Study | COMPLETED | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 6 | |
| Overall Study | NOT COMPLETED | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 26 |
Source ClinicalTrials.gov
Adverse events154
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 4 | 32 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 2 | 32 | |
| other | Akathisia | Nervous system disorders | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 1 | 32 | |
| other | Alanine aminotransferase increased | Investigations | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 19 | 32 | |
| other | Alkaline phosphatase increased | Investigations | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 6 | 32 | |
| other | Allergic reaction | Investigations | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 1 | 32 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 9 | 32 | |
| other | Anemia | Blood and lymphatic system disorders | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 10 | 32 | |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 5 | 32 | |
| other | Anxiety | Psychiatric disorders | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 4 | 32 |
1 to 10 of 154Source ClinicalTrials.gov
See all 154 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 1 | 32 |
| Total, other adverse events | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 32 | 32 |
| Total, serious adverse events | Treatment (Pazopanib Hydrochloride) Patients Receive Pazopanib Hydrochloride PO QD on Days 1-28 | 12 | 32 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30236511 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01436227
GET https://conductscience.org/api/trials/v1/NCT01436227/events?page=2